Skip to main content

Table 3 PARP inhibitors in ovarian cancer—phase II–III ongoing studies

From: Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

ClinicalTrials.gov Identifier Responsible party Ph Drugs
NCT01033292 Sanofi II CBDC/GEM with INI in Pts with platinum-resistant recurrent EOC
NCT01033123 Sanofi II CBDC/GEM with INI in Pts with platinum-sensitive recurrent EOC
NCT00677079 Sanofi II INI in Pts with BRCA-1 or BRCA-2 associated advanced EOC
NCT01482715 Clovis Oncology, Inc. II RUC in Pts with gBRCA Mutation EOC
NCT01891344 Clovis Oncology, Inc. II RUC in Pts with platinum-sensitive, relapsed, HGSOC (ARIEL2)
NCT01968213 Clovis Oncology, Inc. III RUC as switch maintenance after platinum in relapsed HGSOC (ARIEL3)
NCT00664781 Cancer Research UK II RUC in known carriers of a BRCA 1 or BRCA 2 mutation with advanced EOC
NCT01690598 Vejle Hospital II VEL and TOP for Pts with platinum-resistant or partially platinum-sensitive relapse of EOC with negative or unknown BRCA status
NCT01472783 Vejle Hospital II VEL for Pts with BRCA germline mutation and platinum-resistant or partially platinum-sensitive relapse of EOC
NCT01113957 AbbVie (Abbott) II VEL with TEM vs PLD alone in subjects with recurrent HGSOC
NCT01306032 National Cancer Institute II VEL in combination with metronomic oral CYC in refractory BRCA-positive EOC
NCT02470585 AbbVie III CBDC/P with or without concurrent and continuation maintenance VEL in subjects with previously untreated stages III or IV HGSOC
NCT01540565 National Cancer Institute II VEL in persistent or recurrent EOC with germline BRCA1/BRCA2 mutation
NCT02392676 AstraZeneca III PLA controlled study of OLA maintenance in Pts With platinum sensitive relapsed EOC and loss of function somatic BRCA mutation(s) or loss of function mutation(s) in tumour homologous recombination repair-associated genes
NCT01874353 AstraZeneca III PLA controlled study of OLA maintenance in platinum sensitive relapsed BRCA mutated EOC Pts with a complete or partial response following platinum based CT
NCT02571725 New Mexico Cancer Care Alliance II Combination of OLA and TREM, in BRCA1 and BRCA2 mutation carriers with recurrent EOC
NCT01844986 AstraZeneca III OLA maintenance in Pts With BRCA mutated advanced EOC following first line platinum based CT
NCT01081951 AstraZeneca III OLA With P and CBDC vs P and CBDC alone in Pts with platinum sensitive advanced EOC
NCT02503436 AstraZeneca II OLA treated BRCAm EOC POPULATION
NCT02282020 AstraZeneca III OLA vs Physician’s choice single agent CT for platinum sensitive relapsed EOC in Pts carrying germline BRCA1/2 mutations
NCT02484404 National Institutes of Health Clinical Center (National Cancer Institute) II Anti-programmed death ligand-1 antibody MEDI4736 in combination With OLA or CED for advanced solid tumors and advanced or recurrent EOC
NCT02340611 University Health Network, Toronto II Combination CED-OLA at the time of disease progression on OLA in EOC
NCT01661868 Ursula A. Matulonis, MD, Dana-Farber Cancer Institute II OLA for Pts with recurrent BRCA deficient EOC with no prior PARP exposure or prior PARP inhibitor exposure
NCT02477644 ARCAGY/GINECO GROUP III OLA or PLA in with platinum-taxane and BV and as maintenance therapy
NCT02345265 National Cancer Institute II OLA and CED for the treatment of recurrent EOC
NCT02208375 M.D. Anderson Cancer Center II OLA With AZD2014 or AZD5363 for recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer
NCT02502266 National Cancer Institute II/III CED and OLA compared to CED or OLA alone, or standard of care CT in women with recurrent platinum-resistant or -refractory EOC
NCT02489006 University Health Network, Toronto II OLA in Pts with platinum sensitive recurrent HGSOC
NCT00628251 AstraZeneca II OLA vs intravenous liposomal doxorubicin given monthly in Pts with advanced BRCA1- or BRCA2-associated EOC who have failed previous platinum-based CT
NCT02485990 Sidney Kimmel Comprehensive Cancer Center II TREM alone or combined with OLA for recurrent or persistent EOC
NCT01116648 National Cancer Institute II CED and OLA for recurrent papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent TNBC
NCT01078662 AstraZeneca II OLA in Pts with advanced cancers BRCA 1 and/or BRCA2 mutation
NCT00494442 AstraZeneca II OLA twice daily in Pts with advanced BRCA1 or BRCA2 associated EOC
NCT00679783 AstraZeneca II OLA in Pts with known BRCA or recurrent HGSOC and in known BRCA or TNBC
NCT00753545 AstraZeneca II OLA Pts with platinum sensitive relapsed serous EOC following treatment with two or more platinum containing regimens
NCT02326844 National Institutes of Health Clinical Center (National Cancer Institute) II TAL in Pts with deleterious BRCA1/2 mutation-associated EOC who have had prior PARP inhibitor treatment
NCT01989546 National Cancer Institute II TAL in Pts with advanced solid tumors and deleterious BRCA mutations
NCT01847274 Tesaro, Inc. III Maintenance with NIR vs PLA in Pts with platinum sensitive EOC
NCT02354131 Nordic Society for Gynaecologic Oncology II NIR and/or NIR-BV combination against BV alone in HRD platinum-sensitive EOC
NCT02354586 Tesaro, Inc. II NIR in women with advanced, relapsed, HGSOC, fallopian tube, or primary peritoneal cancer who have received at least three previous CT regimens
NCT02657889 Tesaro, Inc. II NIR With PEM in Pts with advanced TNBC and in Pts with recurrent EOC
NCT02655016 Tesaro, Inc. III NIR maintenance in Pts With HRD-positive advanced EOC following response on front-line platinum-based CT
NCT02446600 National Cancer Institute III Comparing OLA or CED and OLA to standard platinum-based CT in women with recurrent platinum-sensitive EOC
NCT01434316 National Cancer Institute I VEL and DIN given together with or without CBDC
CRUK/13/023 Cancer Research UK III OLA with CED vs CED and PLA as maintenance therapy following platinum-based CT with CED
  1. Reference: https://www.clinicaltrials.gov; http://www.cancerresearchuk.org
  2. EOC epithelial ovarian cancer, OLA olaparib, VEL veliparib, CED cediranib, RUC rucaparib, DIN dinaciclib, NIR niraparib, TAL talazoparib, GEM gemcitabine, TOP topotecan, PEM pembrolizumab, TREM tremelimumab, CYC cyclophosphamide, TEM temozolomide, PLD pegylated liposomal doxorubicin, PLA placebo, mt mutated, wt wild type, Pts patients, P paclitaxel, CBDC carboplatin, TNBC triple-negative breast cancer, Ph phase